MyoKardia announces accelerates timing for mavacamten topline phase 3 data
MyoKardia announced patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating patients with obstructive hypertrophic cardiomyopathy. Enrollment into the pivotal trial is expected to be completed by mid-August. July 18, 2019